Improved thiopurine formulations and methods of treatment
By combining 6-TG with polyethylene oxide polymer and using enteric coating technology, the problems of insufficient dissolution time and uneven release curve of 6-TG preparation are solved, and efficient local release and safety in the inflammatory site are achieved Increased sex.
Patent Information
- Application Number
- CN202380030374.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-25
- Filing Date
- 2023-03-24
- Publication Date
- 2024-11-12
AI Technical Summary
The existing 6-thioguanine (6-TG) preparations have problems with insufficient dissolution time and uneven release curves when treating inflammatory bowel disease, resulting in insufficient local anti-inflammatory effects at the inflammatory site and are often accompanied by severe liver. Vascular side effects.
Polyethylene oxide polymers with molecular weights between about 900,000 g/mol and 9,000,000 g/mol combined with 6-TG to form a pharmaceutical composition and controlled release through enteric coating technology to ensure distal intestinal Extended release and zero-order dynamic release are achieved.
The uniform distribution of 6-TG in the inflammatory site and local high concentration release are achieved, reducing systemic absorption and hepatic vascular toxic side effects, and improving the local anti-inflammatory effect and safety of the treatment.
Smart Images

Figure BDA0005059580380000231 
Figure BDA0005059580380000251 
Figure BDA0005059580380000252
Abstract
Description
Technical Field
[0001] The present invention generally relates to improved 6-thioguanine (6-TG) preparations, methods of making the same, and uses thereof in therapeutic methods.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority from Australian Provisional Application No. 2022900759, the entire contents of which are hereby incorporated by reference in their entirety. Background Art
[0004] The thiopurine compounds 6-mercaptopurine (6-MP; 3,7-dihydropurine-6-thione) and azathioprine (AZA; 6-(3-methyl-5-nitroimidazol-4-yl)thio-7H-purine) are prodrugs that are metabolized via the salvage pathway of purine metabolism to form 6-thioguanosine triphosphate (6-TGTP) as the major active metabolite. AZA and 6-MP are used to treat a variety of diseases and conditions, such as inflammatory conditions; cancer; autoimmune conditions; and post-transplant immunosuppression. These compounds are also used in therapy for inflammatory bowel disease (IBD), despite the generally long onset of clinical activity of three to four months and the relatively narrow margin between the desired clinical endpoint of controlled immunosuppression and the side effect of leukopenia.
[0005] Conversion of AZA or 6-MP by some cells in the body, including hepatocytes and leukocytes, produces active metabolites in the form of thioguanine nucleotides (6-TGN; primarily 6-TGTP and, to a lesser extent, 6-TGMP and 6-TGDP). This metabolic pathway is schematically outlined in Figure 1 middle.
[0006] 6-TGTP acts on activated circulating T lymphocytes, resulting in proliferation arrest and then apoptosis. The reduction of intestinal homing circulating immune cells can shut down the amplification of inflammation at the site of IBD by the adaptive immune system. However, the metabolic rate of AZA / 6-MP to thioguanine nucleotides (6TGN) is limited by inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase (GMPS). It takes several days for AZA / 6-MP metabolism to produce 6-TGN, wherein it takes at least about four weeks to reach a stable state. Pharmacodynamic effects (i.e., clinical effects) usually require three to four months to achieve. In addition, methylated metabolites such as me6MP, me6MPr and meTIMP are also produced during the conversion of AZA and 6-MP. These high levels of methylated metabolites are associated with many undesirable side effects, including hepatotoxicity, nausea, extreme fatigue, myalgia, pancreatitis and bone marrow suppression (beyond the prediction of the immunosuppressive effect induced by 6-TGTP). These side effects are severe in a large proportion of patients prescribed 6-MP or AZA, and this factor, along with the slow onset of action, limits the use of 6-MP and AZA.
[0007] According to current clinical practice, the alternative thiopurine compound 6-thioguanine (6-TG; 2-amino-6,7-dihydro-3H-purine-6-thione) may be prescribed as an alternative in cases where 6-MP or AZA therapy is unsuccessful.
[0008] 6-TG is converted to TGN, but is not functionally equivalent to 6-MP or AZA therapy. Figure 1 , 6-TG is converted to 6-TGTP (the same major active metabolite as 6-MP or AZA), but 6-TG is more directly metabolized by hypoxanthine-guanine phosphoribosyltransferase (HPRT), that is, 6-MP or AZA is metabolized to form the same major active metabolite, but the metabolic pathways are different. 6-TG is first converted to a monophosphate analog (6-TGMP) by HPRT and then converted to the active metabolite 6-TGTP by kinase. Fewer metabolic steps are required to convert 6-TG into an active drug, and the rate of 6-TG conversion is not limited by the enzymes IMPDH and GMPS. Therefore, the conversion of 6-TG to 6-TGTP is significantly faster than 6-MP or AZA, so the use of 6-TG can be more effective clinically. In addition, the major adverse effects associated with methylated metabolites produced during the metabolism of 6-MP or AZA do not occur during the metabolism of 6-TG.
[0009] Unfortunately, the more rapid onset of 6-TG therapy is closely associated with severe hepatotoxic side effects that can lead to hepatic vascular disease, including sinusoidal obstructive syndrome (SOS); veno-occlusive disease (VOD); or nodular regenerative hyperplasia (NRH). These vascular hepatotoxic side effects, which are uncommon with 6-MP or AZA, are related to high concentrations of 6-TG in the portal circulation, especially when 6-TG is used in high doses.
[0010] When 6-TG is administered to IBD patients in an immediate release form (bolus dose), it is systemically converted to 6-TGTP by the liver and leukocytes. It is believed that 6-TGTP acts on circulating leukocytes (especially T lymphocytes), thereby mediating beneficial immunomodulation to treat IBD. 6-TG preparations are generally designed to provide a considerable systemic concentration of 6-TGN to provide the desired immunosuppressive function. In order to minimize adverse hepatovascular side effects, extended release preparations that provide a 3-hour extended release profile of 6-TG have been developed. Most of the 6-TG in these preparations is released in the proximal small intestine, thereby achieving maximum systemic absorption of 6-TG at a controlled rate while minimizing the effects of high portal C max Caused toxicity.
[0011] Recently, it was found that 6-TG does not require T lymphocytes and B lymphocytes to improve colitis. 6-TG can play a therapeutic role in a way independent of the adaptive immune system. 6-TG can act quickly locally at the site of inflammation and be converted into an active metabolite 6-TGTP by intestinal mucosal and luminal bacteria without producing significant systemic concentrations. Low doses of 6-TG, rather than 6-MP, produce rapid local anti-inflammatory effects in the colon without producing significant immunosuppressive effects. In addition, targeted release provides a method for treating IBD, which provides a faster mechanism of action that does not produce significant systemic concentrations of 6-TGN, thereby solving the toxic and side effects of 6-TG, i.e., vascular hepatotoxicity (such as SOS) and excessive immunosuppression caused by the rapid anabolism of 6-TG. This targeted 6-TG administration is effective because active metabolites are produced and released at the site of inflammation. Due to poor absorption in the colon, vascular hepatotoxicity and bone marrow suppression are minimized, and the therapeutic effect is mainly achieved by the effect of local low-dose 6-TG on the distal intestine.
[0012] We further demonstrated that intrarectal administration of 6-TG improved spontaneous colitis in the distal colon of a mouse model over a 14-day period. There was no improvement in colitis in the mid-colon or proximal colon, suggesting that the beneficial effects of 6-TG are local. Intrarectal administration of 6-MP did not result in any significant improvement in colitis, suggesting a lack of functional equivalence of 6-TG and 6-MP / AZA. Thus, local delivery of 6-TG to sites of intestinal inflammation in IBD offers significant advantages over current immunomodulatory thiopurine therapies.
[0013] However, challenges remain in preparing 6-TG formulations that provide sufficiently long dissolution times and exhibit a zero-order linear release profile in order to evenly distribute 6-TG in the distal intestine, thereby providing local anti-inflammatory effects at sites of inflammation.
[0014] Improved formulations are needed to address one or more challenges of the prior art.
[0015] The reference to any prior art in this specification does not constitute an acknowledgement or implication that this prior art forms part of the common general knowledge in any jurisdiction, nor does it mean that this prior art can be reasonably understood, regarded as relevant, and / or combined with other prior art by a person skilled in the art. Summary of the invention
[0016] In one aspect, the invention provides a pharmaceutical composition comprising 6-thioguanine (6-TG) and a polyethylene oxide polymer having a molecular weight between about 900,000 g / mol and about 9,000,000 g / mol.
[0017] In one embodiment, the composition is formulated for oral administration.
[0018] In one embodiment, the composition is formulated to release 6-TG in the distal intestine.
[0019] In one embodiment, the molecular weight of the polyethylene oxide polymer is greater than about 900,000 g / mol and less than about 9,000,000 g / mol. In one embodiment, the molecular weight of the polyethylene oxide polymer is greater than about 900,000 g / mol and less than about 7,000,000 g / mol. In one embodiment, the molecular weight of the polyethylene oxide polymer is between about 1,000,000 g / mol and 6,000,000 g / mol; between about 1,000,000 g / mol and 5,000,000 g / mol; between about 1,000,000 g / mol and 4,000,000 g / mol; between about 1,000,000 g / mol and 3,000,000 g / mol.
[0020] In one embodiment, the molecular weight of the polyethylene oxide polymer is about 900,000 g / mol; 1,000,000 g / mol; 1,100,000 g / mol; 1,200,000 g / mol; 1,300,000 g / mol; 1,400,000 g / mol; 1,500,000 g / mol; 1,600,000 g / mol; 1,700,000 g / mol; 1,800,000 g / mol; 1,900,000 g / mol; 2,000,000 g / mol; 2,000,000 g / mol; 2,100,000 g / mol; 2,200,000 g / mol; 2, 300,000g / mol; 2,400,000g / mol; 2,500,000g / mol; 2,600,000g / mol; 2,700,000g / mol; 2,800,000g / mol; 2,900,000g / mol; 3,000,000g / mol; 3,100, 000g / mol; 3,200,000g / mol; 3,300,000g / mol; 3,400,000g / mol; 3,500,000g / mol; 3,600,000g / mol; 3,700,000g / mol; 3,800,000g / mol; 3,900,000g / mol; 4,000,000g / mol; 4,100,000g / mol; 4,200,000g / mol; 4,300,000g / mol; 4,400,000g / mol; 4,500,000g / mol; 4,600,000g / mol; 4,700,000g / mol; 5,600 ,000g / mol; 5,700,000g / mol; 5,800,000g / mol; 5,900,000g / mol; 6,000,000g / mol; 6,100,000g / mol; 6,200,000g / mol; 6,300,000g / mol; 6,400,000g / mol; 6,500,000g / mol; 6,600,000g / mol; 6,700,000g / mol; 6,800,000g / mol; 6,900,000g / mol; 7,000,000g / mol; 7,100,000g / mol; 7,200,000g / mol;7,300,000g / mol; 7,400,000g / mol; 7,500,000g / mol; 7,600,000g / mol; 7,700,0 00g / mol; 7,800,000g / mol; 7,900,000g / mol; 8,000,000g / mol; 8,100,000g / mol; 8,200,000g / mol; 8,300,000g / mol; 8,400,000g / mol; 8,500,000g / mol; 8,600,0 00g / mol; 8,700,000g / mol; 8,800,000g / mol; 8,900,000g / mol or 9,000,000g / mol. ;
[0021] In one embodiment, the molecular weight of the polyethylene oxide polymer is about 900,000 g / mol. In one embodiment, the molecular weight of the polyethylene oxide polymer is about 1,000,000 g / mol. In one embodiment, the molecular weight of the polyethylene oxide polymer is about 2,000,000 g / mol. In one embodiment, the molecular weight of the polyethylene oxide polymer is about 4,000,000 g / mol. In one embodiment, the molecular weight of the polyethylene oxide polymer is about 5,000,000 g / mol. In one embodiment, the molecular weight of the polyethylene oxide polymer is about 7,000,000 g / mol.
[0022] In one embodiment, the polyethylene oxide polymer has a molecular weight of about 2,000,000 g / mol.
[0023] In one embodiment, the polyethylene oxide polymer comprises two or more different approximate molecular weights.
[0024] In one embodiment, the polyethylene oxide polymer comprises essentially a single approximate molecular weight.
[0025] In one embodiment, the pharmaceutical composition is a tablet.
[0026] In one embodiment, the tablet comprises a core and a coating.
[0027] In one embodiment, the tablet includes about 1 to 50 mg of 6-TG in each tablet. In one embodiment, the tablet includes about 1 to 40 mg of 6-TG in each tablet. In one embodiment, the tablet includes about 1 to 30 mg of 6-TG in each tablet. In one embodiment, the tablet includes about 1 to 20 mg of 6-TG in each tablet. In one embodiment, the tablet includes about 5 to 20 mg of 6-TG in each tablet.
[0028] In some embodiments, the tablet comprises about 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, or 50 mg of 6-TG.
[0029] In one embodiment, the tablet comprises about 10 mg of 6-TG.
[0030] In one embodiment, 6-TG is present in an amount of about 1 to 30% w / w of the pharmaceutical composition. In one embodiment, 6-TG is present in an amount of about 1 to 20% w / w of the pharmaceutical composition. In one embodiment, 6-TG is present in an amount of about 1 to 10% w / w of the pharmaceutical composition. In one embodiment, 6-TG is present in an amount of about 1 to 5% w / w of the pharmaceutical composition. In one embodiment, 6-TG is present in an amount of about 2 to 4% w / w of the pharmaceutical composition.
[0031] In one embodiment, 6-TG is present in an amount of about 1 to 30% w / w of the core. In one embodiment, 6-TG is present in an amount of about 1 to 10% w / w of the core. In one embodiment, 6-TG is present in an amount of about 2 to about 3% w / w.
[0032] In one embodiment, the polyethylene oxide polymer comprises about 60 to 98% w / w of the pharmaceutical composition. In one embodiment, the polyethylene oxide polymer comprises about 65 to 98% w / w of the pharmaceutical composition. In one embodiment, the polyethylene oxide polymer comprises about 70 to 98% w / w of the pharmaceutical composition. In one embodiment, the polyethylene oxide polymer comprises about 80 to 98% w / w of the pharmaceutical composition. In one embodiment, the polyethylene oxide polymer comprises about 85 to 98% w / w of the pharmaceutical composition.
[0033] In one embodiment, the polyethylene oxide polymer comprises about 70 to 99% w / w of the core of the tablet. In one embodiment, the polyethylene oxide polymer comprises about 75 to 99% w / w of the core of the tablet. In one embodiment, the polyethylene oxide polymer comprises about 80 to 99% w / w of the core of the tablet. In one embodiment, the polyethylene oxide polymer comprises about 85 to 99% w / w of the core of the tablet. In one embodiment, the polyethylene oxide polymer comprises about 85 to 98% w / w of the core of the tablet.
[0034] In one embodiment, the ratio of the 6-TG to the polyethylene oxide polymer is about 1:20 to 1:50, preferably about 1:30 to 1:40, more preferably about 1:35.
[0035] In one embodiment, the ratio of 6-TG to the polyethylene oxide polymer having a molecular weight of about 2,000,000 g / mol is about 1:30 to 1:40, preferably about 1:35.
[0036] In one embodiment, the pharmaceutical composition includes a lubricant.
[0037] In one embodiment, the core of the pharmaceutical composition comprises a lubricant.
[0038] In one embodiment, the lubricant is selected from any one or more of the following: magnesium stearate, stearic acid, calcium stearate, zinc stearate, polyethylene glycol, talc, sodium lauryl sulfate, magnesium lauryl sulfate, adipic acid and paraffin.
[0039] In one embodiment, the lubricant comprises magnesium stearate.
[0040] In one embodiment, the pharmaceutical composition comprises about 0.2 to 5% w / w of the lubricant.
[0041] In one embodiment, the core of the pharmaceutical composition comprises about 0.2 to 5% w / w of the lubricant.
[0042] In one embodiment, the core of the pharmaceutical composition comprises about 0.5 to 2% w / w of the lubricant.
[0043] In one embodiment, wherein the pharmaceutical composition is a tablet, the tablet comprises a coating.
[0044] In one embodiment, the coating is an enteric coating.
[0045] In one embodiment, the enteric coating is capable of dissolving at a pH of at least 5.5, about 5.5, or greater than 5.5. In another embodiment, the enteric coating is capable of dissolving at a pH of at least 6.5, about 6.5, or greater than 6.5.
[0046] In a preferred embodiment, the enteric coating comprises a polymer that is soluble at a pH of at least 5.5, about 5.5, greater than about 5.5, at least 6.5, about 6.5, or greater than about 6.5. In one embodiment, the polymer of the enteric coating comprises cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, methacrylic acid copolymer, or a combination thereof. In one embodiment, the methacrylic acid copolymer comprises poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid), methacrylic acid-ethyl acrylate 1:1 copolymer, methacrylic acid-methyl methacrylate 1:1 copolymer, methacrylic acid-methyl methacrylate 1:2 copolymer, or a mixture thereof.
[0047] In one embodiment, the molecular weight of the methacrylic acid-ethyl acrylate (1:1) copolymer is between about 200,000 g / mol and about 400,000 g / mol.
[0048] In one embodiment, the enteric coating comprises one or more excipients selected from the group consisting of plasticizers, anti-adherents, surfactants, defoaming agents, and mixtures thereof.
[0049] In one embodiment, the enteric coating comprises about 5 to 20% w / w of the tablet. In one embodiment, the enteric coating comprises about 5 to 15% w / w of the tablet. In one embodiment, the enteric coating comprises about 7 to 12% w / w of the tablet. In one embodiment, the enteric coating comprises about 10% w / w of the tablet.
[0050] In one embodiment, the pharmaceutical composition is a tablet containing 10 mg of 6-TG, which is formulated to release 6-TG at a rate of about 0.2 to 0.8 mg / hour over at least 12 hours when the release is measured at a pH of about 6.8 when subjected to in vitro dissolution testing as described herein.
[0051] In one embodiment, the pharmaceutical composition is a tablet containing 10 mg of 6-TG, which is formulated to release 6-TG at a rate of about 0.3 to 0.5 mg / hour over at least 20 hours when the release is measured at a pH of about 6.8 when subjected to in vitro dissolution testing as described herein.
[0052] In one embodiment, the pharmaceutical composition is formulated to provide approximately zero-order kinetics of 6-TG release.
[0053] In one embodiment, the pharmaceutical composition is formulated to provide approximately zero order kinetics of 6-TG release when the release is measured at a pH of about 6.8 when subjected to in vitro dissolution testing as described herein.
[0054] In one embodiment, the pharmaceutical composition is formulated to release 6-TG at an approximately constant rate when measured at a pH of about 6.8 when subjected to in vitro dissolution testing as described herein, wherein R 2 Values range from approximately 0.98 to 1.
[0055] In one embodiment, the core provides at least about 30% release of the 6-TG in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8) within about 10 hours.
[0056] In one embodiment, the pharmaceutical composition provides at least 30% release of the 6-TG in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8) within about 10 hours.
[0057] In preferred embodiments, the pharmaceutical composition provides at least 70% release of the 6-TG in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8) within about 20 hours.
[0058] In another preferred embodiment, the pharmaceutical composition provides at least 85%, preferably at least 90%, more preferably at least 95% release of the 6-TG in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8) within about 30 hours.
[0059] In one embodiment, the core provides less than about 10% release of the 6-TG in about 2 hours in vitro at less than about pH 5.5 (preferably pH 1.1).
[0060] In one embodiment, the pharmaceutical composition provides less than about 10% release of the 6-TG in vitro at less than about pH 5.5 (preferably pH 1.1) within about 2 hours.
[0061] In one embodiment, the pharmaceutical composition provides less than 80% release of the 6-TG in about 10 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8).
[0062] In one embodiment, the pharmaceutical composition provides less than 60% release of the 6-TG in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8) within about 10 hours.
[0063] In one embodiment, the pharmaceutical composition provides less than 50% release of the 6-TG in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8) within about 10 hours.
[0064] In one embodiment, the pharmaceutical composition:
[0065] Provides at least 30% release of said 6-TG in about 10 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8), and
[0066] Provides less than 80%, preferably less than 60%, more preferably 50% release of said 6-TG in about 10 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8).
[0067] In one embodiment, the pharmaceutical composition:
[0068] Provides at least 70% release of said 6-TG in about 20 hours at about pH 5.5 to about pH 7.5 (preferably pH 6.8) in vitro, and
[0069] Provides less than 80%, preferably less than 60%, more preferably 50% release of said 6-TG in about 10 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8).
[0070] In one embodiment, the pharmaceutical composition:
[0071] Provides at least 85%, preferably at least 90%, more preferably at least 95% release of said 6-TG in about 30 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8), and
[0072] Provides less than 80%, preferably less than 60%, more preferably 50% release of said 6-TG in about 10 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8).
[0073] In one embodiment, the pharmaceutical composition:
[0074] provides at least 30% release of said 6-TG in about 10 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8),
[0075] provides at least 70% release of said 6-TG in about 20 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8),
[0076] Provides at least 85%, preferably at least 90%, more preferably at least 95% release of said 6-TG in about 30 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8), and
[0077] Provides less than 80%, preferably less than 60%, more preferably less than 50% release of said 6-TG in about 10 hours in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8).
[0078] In one embodiment, said pharmaceutical composition provides at least 80% release of said 6-TG in said distal intestine.
[0079] In one embodiment, the pharmaceutical composition provides at least 80%, preferably at least 90%, more preferably at least 95% release of the 6-TG within about 32 hours from oral administration.
[0080] In one embodiment, the pharmaceutical composition provides at least 30% release of the 6-TG in vivo at about 12 hours after oral administration.
[0081] In one embodiment, the pharmaceutical composition is formulated to minimize substantial systemic concentrations of 6-TG.
[0082] In one embodiment, the pharmaceutical composition includes an additional active agent for treating a disease or condition responsive to 6-TG.
[0083] In another aspect, the present invention provides a pharmaceutical composition as described herein, wherein the composition is used to treat an inflammatory disease or condition of the distal intestine that is responsive to 6-TG, such as inflammatory bowel disease.
[0084] In another aspect, the present invention provides a use of a pharmaceutical composition as described herein, wherein the composition is for treating an inflammatory disease or condition of the distal intestine that is responsive to 6-TG, such as inflammatory bowel disease.
[0085] In another aspect, the present invention provides a method for treating a disease or condition responsive to 6-TG in the distal intestine of an individual in need thereof, the method comprising administering a pharmaceutical composition as described herein, wherein the 6-TG is released in the distal intestine (as defined herein). Preferably, the substantial systemic concentration of 6-TG is minimized. Preferably, the 6-TG is metabolized by luminal bacteria or diseased mucosa at the site of inflammation associated with the disease or condition.
[0086] In yet a further aspect, the invention provides a method as described herein, further comprising administering an additional active agent for treating a disease or condition responsive to 6-TG.
[0087] In yet another aspect, the present invention provides a use of a polyethylene oxide polymer having a molecular weight of between about 900,000 and about 9,000,000 g / mol of 6-TG, optionally comprising an enteric coating, in the manufacture of a medicament, wherein the medicament is formulated to treat a disease or condition of the distal intestine (as defined herein) that is responsive to 6-TG by releasing the 6-TG in the distal intestine.
[0088] In one embodiment, the medicament or the pharmaceutical composition is formulated to provide a dosage of about 1 to 50 mg 6-TG per day.
[0089] In one embodiment, the medicament or the pharmaceutical composition is formulated to provide a dosage of about 1 to 40 mg 6-TG per day.
[0090] In one embodiment, the medicament or the pharmaceutical composition is formulated to provide a dosage of about 1 to 30 mg 6-TG per day.
[0091] In one embodiment, the medicament or the pharmaceutical composition is formulated to provide a dosage of about 5 to 30 mg 6-TG per day.
[0092] In one embodiment, the medicament or the pharmaceutical composition is formulated to provide a dosage of about 5 to 20 mg 6-TG per day.
[0093] In one embodiment, the medicament or the pharmaceutical composition is formulated to provide a dosage of about 10 to 20 mg 6-TG per day.
[0094] In one embodiment, the medicament or the pharmaceutical composition is formulated to provide a dosage of about 10 mg 6-TG per day.
[0095] For the avoidance of doubt, where the context permits, embodiments may apply to any one or more of the above aspects, alone or in any combination of two or more thereof.
[0096] Further aspects of the invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, which is given by way of example and with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0097] Figure 1 is a schematic diagram showing the metabolic pathway of thiopurines. Thiopurine :AZA: azathioprine; 6MP: 6-mercaptopurine; TG: 6-thioguanine; Thiopurine nucleotides :TGMP: thioguanosine monophosphate; TGDP: thioguanosine diphosphate; TGTP: thioguanosine triphosphate; Anabolic enzymes and metabolites : IMPDH: inosine monophosphate dehydrogenase; GMPS: guanosine monophosphate synthase; TIMP: thioinosine monophosphate; ITPA: inosine triphosphate; HPRT: hypoxanthine guanine phosphoribosyltransferase.
[0098] Figure 2 A graphical representation of the cumulative release of 6-TG from Core Formulation 1 over 30 hours is shown.
[0099] Figure 3 A graphical representation of the cumulative release of 6-TG from Core Formulation 2 over 30 hours is shown.
[0100] Figure 4A graphical representation of the cumulative release of 6-TG from Core Formulation 3 over 30 hours is shown.
[0101] Figure 5 A graphical representation of the cumulative release of 6-TG from Core Formulation 4 over 30 hours is shown.
[0102] Figure 6 Shown is a graphical representation of the cumulative release of 6-TG from Formulation 5 (enteric coated) over 36 hours (pH 1.1 at 1-2 hours, pH 6.5 at 3 hours, pH 6.8 at 4-36 hours).
[0103] Figure 7 A and 7B show graphical representations of a typical thioguanine standard UV spectrum (A) and a typical sample solution UV spectrum (B).
[0104] Figure 8 Shown is a graphical representation of the cumulative release of 6-TG over 30 hours from the formulation of Example 10 (enteric coated) (at pH 1.1 at 1-2 hours, at pH 5.5 at 3 hours, at pH 6.8 at 4-30 hours).
[0105] Definition of terms
[0106] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar to or equivalent to the methods and materials described herein may be used in the practice or testing of the present invention, preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.
[0107] The articles "a" and "an" are used herein to refer to one or to more than one (ie, to at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.
[0108] As used herein, the term "about" refers to an amount, level, concentration, value, size or amount that varies by up to 10% or even up to 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% relative to a reference amount, level, concentration, value, size or amount.
[0109] As used herein, the term "comprise" and variations of the term such as "comprising," "comprises," and "comprised" are not intended to exclude additional additives, components, integers or steps, unless the context requires otherwise.
[0110] As used herein, the term "distal intestine" refers to the segment of the intestine that includes the distal ileum and the large intestine. In some embodiments, the relevant segment of the distal intestine is the large intestine.
[0111] As used herein, the term "large intestine" refers to the colon and rectum. The term "colon" refers to the intestinal segment consisting of the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon. In some embodiments, the relevant segment of the large intestine is the colon. In some embodiments, the relevant segment of the large intestine is the rectum.
[0112] As used herein, the term "proximal and middle small intestine" refers to the duodenum, jejunum, and portion of the ileum excluding the distal ileum (the last being approximately less than or equal to 100 cm of the ileum).
[0113] As used herein, the phrases "a disease or condition of the distal intestine that is responsive to 6-TG," "a disease or condition of the distal ileum and / or large intestine that is responsive to 6-TG," "a disease or condition of the distal ileum, colon and / or rectum that is responsive to 6-TG," and the like refer to any disease or condition of the distal ileum, colon or rectum that can be treated with 6-TG, including any symptom of the treatment of the disease or condition. Preferably, the disease or condition is an inflammatory disease or condition. Examples of such inflammatory diseases or conditions include ulcerative colitis, Crohn's disease, and IBD-U (IBD undifferentiated).
[0114] As used herein, the phrase "inflammatory bowel disease" is a condition that typically affects the distal intestine and encompasses ulcerative colitis, Crohn's disease, and IBD-U (IBD undifferentiated).
[0115] The term "extended release formulation" refers to a formulation that is converted or degraded or metabolized into an active component (e.g., 6-TG) contained therein or provides a source of the active component over an extended period of time. Such formulations may also be referred to as slow release or sustained release formulations in the art.
[0116] The term "extended release" refers to the release of the active pharmaceutical ingredient (6-TG) from a pharmaceutical formulation over an extended period of time, thereby providing continuous local delivery of 6-TG as the formulation passes through the distal intestine. In some embodiments, the extended release of 6-TG has substantially zero-order kinetics.
[0117] The terms "individual", "patient" and "subject" are used interchangeably herein to refer to individuals of human or other animal origin, and include any individual that is desired to be examined or treated using the methods of the present invention. However, it should be understood that these terms do not imply the presence of symptoms. Suitable animals falling within the scope of the present invention include, but are not limited to, humans, primates, livestock (e.g., sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and captive wild animals (e.g., foxes, deer, wild dogs, birds, reptiles).
[0118] The phrase "6-TG side effects" and similar expressions refer to adverse or undesirable side effects caused by 6-TG and / or its 6-TG metabolites (including 6-TGTP (and / or other metabolites)), including but not limited to vascular hepatotoxicity, including sinus obstructive syndrome (SOS), veno-occlusive disease (VOD), and nodular regenerative hyperplasia (NRH); and excessive immunosuppression or bone marrow suppression; and alopecia.
[0119] "Pharmaceutically acceptable excipient, carrier or diluent" refers to a solid or liquid filler, diluent or encapsulating substance that is safe for topical or systemic administration.
[0120] As used herein, the terms "treat", "treating" and "treatment" encompass treatment of a disease or condition that is responsive to 6-TG in an individual suffering from the disease or condition, and include: inhibiting the disease or condition, i.e., preventing its development; alleviating the disease or condition, i.e., causing the disease or condition to regress; or alleviating symptoms caused by the disease or condition, i.e., alleviating pain or inflammation without resolving the underlying disease or condition.
[0121] It should be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident in the text or drawings. All these different combinations constitute various alternative aspects of the invention. DETAILED DESCRIPTION
[0122] The present invention relates to a pharmaceutical composition comprising 6-TG and a polyethylene oxide polymer having a molecular weight between about 900,000 g / mol and about 9,000,000 g / mol. The composition can be formulated to release 6-TG in the distal intestine, preferably the large intestine. Suitably, the composition is formulated to release 6-TG substantially in the distal intestine. Suitably, the composition is formulated for oral administration. Suitably, the pharmaceutical composition is formulated to provide delayed release over an extended period of time after oral administration to release 6-TG substantially in the distal intestine.
[0123] Suitably, the composition is formulated for extended release of 6-TG in the distal intestine. Suitably, the composition releases at least 80% of 6-TG in the distal intestine. In some embodiments, the segment of the distal intestine is the large intestine. Suitably, the composition is used to treat a disease or condition of the distal intestine that is responsive to 6-TG. Suitably, the composition is used to treat IBD, such as ulcerative colitis, Crohn's disease or IBD-U. In some embodiments, the composition may be used to treat microscopic colitis; for example, lymphocytic (entero) colitis and collagenous (entero) colitis.
[0124] The molecular weight of the polyethylene oxide polymer is between about 900,000 g / mol and about 9,000,000 g / mol. Preferably, the molecular weight of the polyethylene oxide polymer is greater than about 900,000 g / mol and less than about 9,000,000 g / mol.
[0125] Preferably, the molecular weight of the polyethylene oxide polymer is between about 1,000,000 g / mol and about 6,000,000 g / mol; between about 1,000,000 g / mol and about 5,000,000 g / mol; between about 1,000,000 g / mol and about 4,000,000 g / mol; between about 1,000,000 g / mol and about 3,000,000 g / mol. More preferably, the molecular weight of the polyethylene oxide polymer is greater than about 1,000,000 g / mol and less than about 6,000,000 g / mol; greater than about 1,000,000 g / mol and less than about 5,000,000 g / mol; greater than about 1,000,000 g / mol and less than about 4,000,000 g / mol; greater than about 1,000,000 g / mol and less than about 3,000,000 g / mol.
[0126] Preferably, the molecular weight of the polyethylene oxide polymer is about 900,000 g / mol; 1,000,000 g / mol; 1,100,000 g / mol; 1,200,000 g / mol; 1,300,000 g / mol; 1,400,000 g / mol; 1,500,000 g / mol; 1,600,000 g / mol; 1,700,000 g / mol; 1,800,000 g / mol; 1,900,000 g / mol; 2,000,000 g / mol; 2,000,000 g / mol; 2,100,000 g / mol; 2,200,000 g / mol; 2,300,000 g / mol; 2,400,000 g / mol; 2,500,000 g / mol; 2,600,000 g / mol; 2,700,000 g / mol; 2,800,000 g / mol; 2,900,000 g / mol; 3,000,000 g / mol; 3,100,000 g / mol; 3,200,000 g / mol; 3,300,000 g / mol; 3,400,000 g / mol; 3,500,000 g / mol; 3,600,000 g / mol; 3,700,000 g / mol; 3,800,000 g / mol; 3,900,000 g / mol; 4,000,000 g / mol; 4,100,000 g / mol; 4,200,000 g / mol; 4,300,000 g / mol; 4,400,000 g / mol; 4,500,000 g / mol; 4,600,000 g / mol; 4,700,000 g / mol; 4,800,000 g / mol; 4,900,000 g / mol; 5,000,000 g / mol; 5,100,000 g / mol; 5,200,000 g / mol; 5,300,000 g / mol; 5,400,000 g / mol; 5,500,000 g / mol; 5,600,000 g / mol; 5,700,000 g / mol; 5,800,000 g / mol; 5,900,000 g / mol; 6,000,000 g / mol; 6,100,000 g / mol; 6,200,000 g / mol; 6,300,000 g / mol; 6,400,000 g / mol; 6,500,000 g / mol; 6,600,000 g / mol; 6,700,000 g / mol; 6,800,000 g / mol; 6,900,000 g / mol; 7,000,000 g / mol; 7,100,000 g / mol; 7,200,000 g / mol;7,300,000g / mol; 7,400,000g / mol; 7,500,000g / mol; 7,600,000g / mol; 7,700,0 00g / mol; 7,800,000g / mol; 7,900,000g / mol; 8,000,000g / mol; 8,100,000g / mol; 8,200,000g / mol; 8,300,000g / mol; 8,400,000g / mol; 8,500,000g / mol; 8,600,0 00g / mol; 8,700,000g / mol; 8,800,000g / mol; 8,900,000g / mol or 9,000,000g / mol. ;
[0127] Preferably, the molecular weight of the polyethylene oxide polymer is greater than about 1,000,000 g / mol and less than about 6,000,000 g / mol. This molecular weight range has been shown to provide extended release of 6-TG in vitro at pH 6.8 over about 30 hours, with substantially linear release over most of the release time.
[0128] Most preferably, the polyethylene oxide polymer has a molecular weight of about 2,000,000 g / mol.
[0129] Polyethylene oxide polymers can include one or more polymers. In one embodiment, polyethylene oxide polymers substantially include a single approximate molecular weight polymer. For example, a polyethylene oxide polymer having a molecular weight between about 900,000g / mol and about 9,000,000g / mol can substantially include a single approximate molecular weight (e.g., about 2,000,000g / mol) polymer. In another embodiment, polyethylene oxide polymers include two or more polymers of different approximate molecular weights, wherein the molecular weight of each polymer is within a defined molecular weight range. For example, a polyethylene oxide polymer having a molecular weight between about 900,000g / mol and about 9,000,000g / mol can include two or more polyethylene oxide polymers, wherein for example the molecular weight of the first polyethylene oxide polymer is about 2,000,000g / mol, and the molecular weight of the second polyethylene oxide polymer is about 7,000,000g / mol. In addition to polyethylene oxide polymers having a molecular weight between about 900,000 g / mol and about 9,000,000 g / mol, the composition may also include additional polyethylene oxide polymers having higher or lower molecular weights.
[0130] It will be apparent to one skilled in the art that, due to the nature of the polymerization reaction, the molecular weights of polyethylene oxide polymers are approximate. Polyethylene oxide polymers are commercially available in a variety of different weights. The weights are approximate or average weights. For example, POLYOX TM (Polyethylene oxide) WSR N-60K (PEO 2,000,000) is available from Dupont with a viscosity range of 2000-4000 mPa-sec (cP) for a 2 weight percent aqueous solution measured at 25°C on a Brookfield viscometer (Model RVF, spindle number / speed rpm 3 / 10).
[0131] In some embodiments, the pharmaceutical composition is a tablet. The tablet may include a core and a coating. An exemplary core includes 6-TG and a polyethylene oxide polymer having a molecular weight between about 900,000 g / mol and about 9,000,000 g / mol, thereby forming a drug-polymer matrix. An exemplary tablet includes a core and an enteric coating.
[0132] In some embodiments, the tablet comprises about 1 to 50 mg, 1 to 40 mg, 1 to 30 mg, 1 to 20 mg, or 5 to 20 mg of 6-TG. Preferably, the tablet comprises about 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, or 50 mg of 6-TG. Preferably, the tablet comprises about 10 mg of 6-TG.
[0133] In some embodiments, the weight of the tablet is about 300 to 500 mg or about 300 to 450 mg. Preferably, the weight of the tablet is about 350 to 400 mg. Preferably, the weight of the core component of the tablet is about 100 mg, 200 mg, 300 mg, 400 mg or 500 mg. More preferably, the weight of the core component of the tablet is about 300 mg to 400 mg or about 320 mg to about 380 mg. Even more preferably, the weight of the core is about 360 mg.
[0134] In some embodiments, 6-TG is present in an amount of about 1 to 30% w / w of the core, or about 1 to 10% w / w of the core, including about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% and 10% w / w of the core, preferably about 2 to about 3% w / w.
[0135] In some embodiments, 6-TG is present in an amount of about 1 to 30% w / w, or about 1 to 20% w / w, or about 1 to 10% w / w, or about 1 to 5% w / w, or about 2 to 4% w / w of the tablet.
[0136] In some embodiments, the polyethylene oxide polymer having a molecular weight between about 900,000 g / mol and about 9,000,000 g / mol is present in an amount of about 70 to about 99% w / w of the core, preferably about 75 to about 99% w / w, 80 to 99% w / w, 85 to 99% w / w, 85 to 98% w / w of the core, especially about 90 to about 98% w / w (including about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% and 98% w / w of the core), and most preferably about 97% w / w.
[0137] In some embodiments, the tablet further comprises one or more pharmaceutically acceptable excipients, such as carriers, diluents, binders and / or lubricants, including excipients that impart the desired consistency, strength, viscosity, texture, and appearance.
[0138] Ethylcellulose can be used to modify the release rate of the core (e.g., to extend the release time). However, preferably, the pharmaceutical composition comprising the enteric coating does not contain ethylcellulose. The use of ethylcellulose may also adversely affect the release kinetics.
[0139] Suitable binders include disaccharides, such as lactose; polysaccharides, such as starches, for example corn starch, starch paste; and sugar alcohols, such as mannitol.
[0140] Suitable lubricants include fats, such as magnesium stearate; talc; or silicon dioxide, such as fumed silica. In one embodiment, the lubricant is selected from any one or more of the following: magnesium stearate, stearic acid, calcium stearate, zinc stearate, polyethylene glycol, talc, sodium lauryl sulfate, magnesium lauryl sulfate, adipic acid and paraffin, preferably magnesium stearate.
[0141] The lubricant may be present in an amount of about 0.2 to 5% w / w of the core, in particular about 0.2 to 4% w / w of the core, in particular about 0.5 to 2% w / w of the core. In one embodiment, the lubricant is present in an amount of about 1 to 2.5% w / w of the core. The lubricant may be present in an amount of about 0.2 to 5% w / w of the pharmaceutical composition.
[0142] The pharmaceutical composition may include about 1 to 30% w / w 6-TG, or about 1 to 20% w / w 6-TG, or about 1 to 10% w / w 6-TG, or about 1 to 5% w / w 6-TG, or about 2 to 4% w / w 6-TG.
[0143] It will be apparent to those skilled in the art that 6-TG can be obtained and / or used as a hydrate (e.g., heptahydrate). When considering the percentage or ratio of 6-TG in a pharmaceutical composition, the mass of water in the hydrate should not be included.
[0144] The ratio of the 6-TG compound to the polyethylene oxide polymer may be about 1:20 to 1:50, such as about 1:30 to 1:40; about 1:35.
[0145] In some embodiments, the ratio of 6-TG to polyethylene oxide polymer having a molecular weight of about 2,000,000 g / mol is about 1:30 to 1:40, preferably about 1:35.
[0146] When the pharmaceutical composition is a tablet comprising a core and a coating, the coating is preferably an enteric coating.
[0147] The present disclosure may be directed to a pharmaceutical composition comprising 6-TG, a polyethylene oxide polymer having a molecular weight between about 900,000 g / mol and 9,000,000 g / mol, and an enteric-coated oral formulation. The composition may be formulated to release 6-TG in the distal intestine, preferably the large intestine.
[0148] Enteric coatings control or delay the release of 6-TG by reducing release in the stomach and / or reducing or substantially preventing the release of 6-TG before the tablet reaches the distal intestine. Suitable enteric coatings are capable of dissolving at a pH of at least 5.5, about 5.5, or greater than 5.5.
[0149] In a preferred embodiment, the enteric coating comprises a polymer that is soluble at a pH of at least 5.5, about 5.5, or greater than 5.5. Preferably, the polymer dissolves at a pH of about 5.5 to about 8. Advantageously, an enteric coating comprising a polymer that is soluble at a pH greater than about 5.5 minimizes or at least reduces disintegration of the composition in the stomach, proximal intestine, and mid-small intestine.
[0150] Preferably, the polymer of the enteric coating that is soluble at a pH of at least 5.5 comprises cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate and / or a copolymer of acrylic acid and its esters or methacrylic acid or its esters. Preferably, the polymer of the enteric coating comprises a methacrylic acid copolymer. Preferably, the polymer comprises poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid), methacrylic acid-ethyl acrylate [1:1] copolymer, methacrylic acid-methyl methacrylate 1:1 copolymer, methacrylic acid-methyl methacrylate 1:2 copolymer or a mixture thereof. More preferably, the molecular weight of the methacrylic acid-ethyl acrylate (1:1) copolymer is between about 200,000 g / mol and about 400,000 g / mol, preferably about 320,000 g / mol. In one embodiment, the coating comprises L30 D-55 or Acryl-EZE powder dispersion, preferably Acryl-EZE 93F19255.
[0151] Enteric coatings can be applied to tablets using conventional techniques known in the art. For example, the coating can be applied using spray, dip, fluidized bed or pan coating techniques, as described, for example, in Remington: The Science and Practice of Pharmacy, Loyd V. Allen, Jr (ed.), The Pharmaceutical Press, 22nd edition, September 2012, Chapter 46.
[0152] In one embodiment, the enteric coating includes one or more pharmaceutically acceptable excipients, carriers and / or diluents. Such excipients, diluents and carriers enable the composition to be formulated into dosage forms such as tablets (including pills, capsules, etc.) for oral administration to individuals. Acceptable excipients, diluents and carriers are well known to those skilled in the art, and include but are not limited to plasticizers, antiadherents, surfactants, defoamers, pigments and mixtures thereof. Suitable plasticizers include but are not limited to triethyl citrate, polyethylene glycol, 1,2-propylene glycol, triacetin, dibutyl phthalate, tributyl citrate, acetyl triethyl citrate and acetyl tributyl citrate. Suitable antiadherents include glyceryl monostearate, talc, silicon dioxide, calcium silicate. Suitable surfactants include polysorbate 80. Suitable defoamers include simethicone, dimethicone, oleyl alcohol.
[0153] In a preferred embodiment, the enteric coating comprises an excipient selected from the group consisting of glyceryl monostearate, triethyl citrate and polysorbate 80, talc, silicon dioxide, polyethylene glycol, triethyl citrate, simethicone and combinations thereof. In a particularly preferred embodiment, the coating comprises talc, silicon dioxide, polyethylene glycol and triethyl citrate. In yet another embodiment, the enteric coating comprises a plasticizer and a defoamer.
[0154] Release curve
[0155] Preferably, the pharmaceutical composition comprising an enteric coating provides delayed release after oral administration and / or at an in vitro pH of less than about 5.5.
[0156] Preferably, the pharmaceutical composition comprising an enteric coating minimizes the release of 6-TG at a pH of less than about 5.5; 5.4; 5.3; 5.2; 5.1; 5.0; 4.9; 4.8; 4.7; 4.6; 4.5; 4.4; 4.3; 4.2; 4.0; 3.9; 3.8; 3.7; 3.6; 3.5; 3.4; 3.3; 3.2; 3.1; 3.0; 2.9; 2.8; 2.7; 2.6; 2.5; 2.4; 2.3; 2.2; 2.1; 2.0; 1.9; 1.8; 1.7; 1.6; 1.5.
[0157] Preferably, when subjected to in vitro dissolution testing as described herein, the tablet comprising the enteric coating provides a release of no more than about 10% of 6-TG in vitro at a pH of less than about 5.5 (preferably about pH 1.1) within a period of about 2 hours or less, preferably no more than about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%.
[0158] Preferably, a pharmaceutical composition formulated for oral administration comprising an enteric coating provides a release of no more than about 10% of 6-TG within about 2 hours from oral administration, or provides a release of no more than about 8% of 6-TG within about 2 hours from oral administration, or provides a release of no more than about 5% of 6-TG within about 2 hours from oral administration.
[0159] Preferably, the pharmaceutical composition including the enteric coating is formulated to release 6-TG in vivo or in vitro at a pH of about 5.5 and above (eg, about pH 6.8, 7, 7.5, or 8).
[0160] Preferably, the pharmaceutical composition provides at least 30% release of 6-TG in vitro at about pH 5.5; 6; 6.5; 6.8; 7; 7.5; most preferably at about pH 6.8 within about 10 hours. Preferably, the pharmaceutical composition provides at least 30% release of 6-TG in vitro at about pH 5.5 to about pH 7.5, most preferably at about pH 6.8 within about 10 hours.
[0161] The pharmaceutical composition preferably provides at least 70% release of 6-TG in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8) within about 20 hours. Preferably, the pharmaceutical composition provides at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83% or at least 84% release of 6-TG in vitro at about pH 5.5 to about pH 7.5, most preferably at about pH 6.8 within about 20 hours.
[0162] Preferably, the pharmaceutical composition provides at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%, more preferably at least 90%, even more preferably at least 95% release of 6-TG in vitro at about pH 5.5 to about pH 7.5, most preferably at about pH 6.8 within about 30 hours.
[0163] In some cases, compositions are defined herein as providing at least a certain percentage of 6-TG release in vitro or in vivo over a specified time period. It will be apparent to the skilled person that this means that at least a minimum defined percentage of 6-TG has been released at a specified time point. For example, at least 35% of 6-TG has been released within 10 hours. More than 35% of 6-TG may have been released within 10 hours, such as 45% or 50% of 6-TG may have been released within 10 hours. This also means that no more than 65% of the 6-TG that has not been released remains after 10 hours, such as no more than 55% or 50% may still remain and have not been released after 10 hours.
[0164] Preferably, the pharmaceutical composition provides less than about 10% release of 6-TG in about 2 hours in vitro at less than about pH 5.5 (preferably pH 1.1).
[0165] Preferably, the pharmaceutical composition provides a release of less than 80% of 6-TG, or less than 60% of 6-TG, or less than 50% of 6-TG in vitro at about pH 5.5 to about pH 7.5 (preferably pH 6.8) within about 10 hours.
[0166] Those skilled in the art know methods for determining in vitro release profiles to simulate pH changes in the gastrointestinal tract. Exemplary methods for determining in vitro release profiles include testing using a dissolution apparatus suitable for tablets, using a medium containing a suitable buffer adjusted to the relevant pH. Dissolution testing can utilize an initial pH adjusted during the test process. The in vitro dissolution test described herein is carried out in a dissolution basket in a buffer of the desired pH (pH 6.8, unless otherwise stated). Dissolution is calculated by measuring the US-vis absorbance of the sample at 341nm compared to a solution of thioguanine of known concentration in the same buffer.
[0167] In a preferred embodiment, a pharmaceutical composition is provided, comprising 6-thioguanine (6-TG) and a polyethylene oxide polymer having a molecular weight greater than about 900,000 g / mol and less than about 7,000,000 g / mol, the pharmaceutical composition being formulated for oral administration, the pharmaceutical composition comprising an enteric coating, wherein the composition:
[0168] - provides a release of no more than about 10%, preferably no more than about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of 6-TG in about 2 hours in vitro at a pH of less than about 5.5, preferably about pH 1.1,
[0169] - provides no more than about 20-30%, preferably no more than about 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29% or 30% release of 6-TG in about 6 hours or less in vitro at about pH 5.5 to about pH 7.5, preferably about pH 6.8, and
[0170] - Provides at least 85% release of 6-TG in vitro at a pH of about 5.5 to about 7.5, preferably pH 6.8, over a period of about 30 hours or more.
[0171] It will be apparent to those skilled in the art that the in vivo release profile can be approximated using in vitro methods.
[0172] The transit time of an oral composition from the mouth to the anus will vary considerably from individual to individual, and many parameters (such as age, solid or liquid food intake, diet, weight, sex, health, intestinal disease state, etc.) will affect the actual transit time. Not all ingested materials are transported at the same rate, so transit is usually measured as 50% clearance of an oral marker ingested at one time. The transit time from the mouth to the duodenum usually varies from about 30 minutes to 90 minutes. The average time for transit from the duodenum through the small intestine into the cecum is about 2-6 hours. The typical transit time from the mouth to the cecum is considered to be about 4-8 hours. The transit time through the colon (from the cecum to the anus) is about 12 to 36 hours. Therefore, the typical transit time from the mouth to the anus is considered to be about 36 hours, but this may vary greatly. Typical transit times may vary from about 16 hours to about 48 hours.
[0173] Suitably, the enteric-coated delayed and extended release oral formulations of the invention are formulated to release or provide 6-TG to the distal intestine, preferably the large intestine. The enteric coating provides a delayed release by limiting the release below about pH 5.5 to minimize or reduce release in the stomach.
[0174] In some embodiments, the oral formulation provides at least 35% 6-TG release of total 6-TG in the distal intestine, preferably the large intestine. In some embodiments, the oral formulation provides at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 6-TG release of total 6-TG in the distal intestine, preferably the large intestine. In some embodiments, the oral formulation provides at least 80% 6-TG release of total 6-TG in the distal intestine, and preferably the large intestine.
[0175] Preferably, the composition comprising a polyethylene oxide polymer having a molecular weight of about 2,000,000 g / mol provides at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%, most preferably at least 80% release of 6-TG within about 30 hours from oral administration. Preferably, the composition comprising a polyethylene oxide polymer having a molecular weight of about 2,000,000 g / mol provides at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%, most preferably at least 95% release of 6-TG within about 30 to 40 hours from oral administration.
[0176] Preferably, the pharmaceutical composition comprising an enteric coating formulated for oral administration provides no more than about 10% (preferably no more than about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0%) of 6-TG release within about 2 hours from oral administration, and provides at least 35% of 6-TG release within about 12 hours after oral administration. Preferably, the pharmaceutical composition provides at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% of 6-TG release within about 30 to 40 hours from oral administration.
[0177] Preferably, the composition is formulated to minimize the substantial systemic absorption of 6-TG. Systemic absorption of orally administered 6-TG occurs primarily in the proximal small intestine. The average time for transit from the duodenum through the small intestine into the cecum is about 2-6 hours. The typical transit time from the oral cavity to the cecum is considered to be about 4-8 hours. In order to minimize the systemic absorption of 6-TG, the pharmaceutical composition is preferably formulated to release no more than about 15-25%, preferably no more than about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% or 25% of 6-TG in about 6 hours or less at about pH 5.5 to about pH 7.5, preferably about pH 6.8 in vitro. The in vitro release profile of no more than about 20% of 6-TG in a period of about 6 hours or less at about pH 5.5 to about pH 7.5, preferably about pH 6.8 in vitro approximates the in vivo release profile, wherein less than about 20% of 6-TG is released no more than 8 hours from oral administration. This release profile significantly reduces systemic 6-TG absorbed from the small intestine.
[0178] Preferably, the pharmaceutical composition comprising an enteric coating formulated for oral administration provides a release of no more than about 10% of 6-TG in an in vitro pH of less than about 5.5 (preferably pH about 1.1) in about 2 hours or less. This release profile approximates the in vivo release profile of no more than about 10% of 6-TG in about 2 hours from oral administration. Most preferably, the formulation does not release a large amount of 6-TG at pH <5.5, preferably no more than about 10% of 6-TG, preferably no more than about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%.
[0179] In a preferred embodiment, a pharmaceutical composition is provided, comprising 6-thioguanine (6-TG) and a polyethylene oxide polymer having a molecular weight between about 900,000 g / mol and about 9,000,000 g / mol, the pharmaceutical composition being formulated for oral administration, the pharmaceutical composition comprising an enteric coating, wherein the composition:
[0180] - provides for a release of no more than about 10%, preferably no more than about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of 6-TG within about 2 hours from oral administration, and / or
[0181] - Provides at least 80% release of 6-TG within about 30 hours from oral administration.
[0182] In preferred embodiments, the formulation provides approximately zero-order kinetics of 6-TG release in the distal intestine (ie, linear delivery relative to extended release time). The zero-order release profile advantageously provides substantially uniform release and distribution of 6-TG as the composition is transported through the distal intestine.
[0183] Suitably, extended release formulations provide substantially zero-order kinetics of 6-TG release after approximately 2 hours, 3 hours, 4 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12 hours after oral administration, preferably approximately 2 hours or approximately 3 hours or approximately 4 hours. Suitably, extended release formulations provide substantially zero-order kinetics of 6-TG release after approximately 2 hours, 3 hours or 4 hours after oral administration, wherein substantially zero-order release keeps at least other 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours or 22 hours, preferably at least other 22 hours. It should be understood that the time end point can be that the preparation residue is discharged from the intestinal tract. Preferably, the formulation provides approximately zero-order kinetics of 6-TG release in vitro at about pH 5.5 to about pH 7.5, preferably wherein substantially zero-order kinetics of release are maintained for at least about 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours or 22 hours, preferably at least about 22 hours. Alternatively, the pharmaceutical composition is formulated to release 6-TG at an approximately constant rate when measured at a pH of about 6.8 when subjected to an in vitro dissolution test as described herein, wherein R 2 The value is between about 0.98 and 1, preferably R 2 The zero order and / or R 2 The values are preferably maintained for up to about 24 hours.
[0184] On the one hand, the present invention provides a kind of pharmaceutical composition, it includes 6-TG and the polyethylene oxide polymer of molecular weight between about 900,000g / mol and about 9,000,000g / mol, the pharmaceutical composition includes enteric coating, wherein the composition is in a form suitable for oral administration, and provides the extended release of 6-TG after a period of about 2 to 8 hours after oral administration. Preferably, the pharmaceutical composition provides the extended release of 6-TG in a period of more than 12 hours after oral administration. Preferably, the release is substantially in the large intestine. Suitably, the composition provides extended release in a period of about 8 hours to 40 hours, preferably about 12 to 40 hours, about 16 to 40 hours or about 20 to 40 hours, about 20 to 36 hours or about 20 to 30 hours after the release starts (for example, in the large intestine and / or the release starts to be more than 2% per hour). Suitably, the composition provides extended release in a pH range of 5.5 to 7.5. It should be understood that the end of time can be that the preparation residue is discharged from the intestinal tract.
[0185] At least one combination of a matrix and a film coating provided in the following description can be used to achieve a desired release profile in different environments encountered during transit through the GI tract. Suitably, the formulation provides a release profile in the distal intestine. More suitably, the formulation provides a release profile in the large intestine.
[0186] Treatment
[0187] Suitably, the pharmaceutical compositions described herein may be used to treat inflammatory diseases or conditions of the distal intestine.
[0188] In one embodiment, a method for treating an inflammatory disease or condition responsive to 6-TG in the distal intestine of an individual in need, the method comprising administering a pharmaceutical composition as described herein to an individual, wherein 6-TG is released in the distal intestine. Preferably, the inflammatory disease or condition of the distal intestine is inflammatory bowel disease (IBD). Preferably, 6-TG is released in the distal intestine. Preferably, 6-TG is released in the large intestine. Examples of the form of IBD include ulcerative colitis, Crohn's disease, and IBD-U (unclassified). Suitably, 6-TG is converted into an active drug by luminal bacteria or diseased mucosa in the distal intestine. Suitably, the systemic concentration of 6-TG is minimized. Suitably, the method minimizes or at least significantly reduces the undesirable 6-TG side effects observed when high portal or systemic concentrations of active or related metabolites are produced, including vascular hepatotoxicity, such as SOS and bone marrow suppression.
[0189] Also provided is a method for treating a disease or condition responsive to 6-TG in an individual in need thereof, the method comprising administering to the individual an oral composition described herein.
[0190] In a preferred embodiment, the method comprises oral administration. Suitably, the method comprises administering a pharmaceutical composition as described herein comprising an enteric coating.
[0191] In some embodiments, the method further comprises administering another active agent for treating a disease or condition responsive to 6-TG in addition to 6-TG, including but not limited to an active agent selected from the group consisting of mesalazine (or 5-aminosalicylic acid), balsalazide, sulfasalazine, corticosteroids, cyclosporine compounds, anti-TNF-a compounds, and combinations thereof. The additional active agent may be administered in one or more compositions identical to the composition comprising 6-TG or in one or more compositions different from the composition comprising 6-TG. The additional active agent may be administered at the same time as the composition comprising 6-TG or at a different time.
[0192] The present invention indicates a combination, kit or commercial package comprising a 6-TG composition and a composition comprising the additional active agent. Such a kit or commercial package may include instructions for use. In some cases, it may be appropriate to provide a composition comprising 6-TG and other active agents. In certain embodiments, the composition does not substantially comprise 6-MP or AZA. In certain embodiments, the composition comprises 6-TG as the only active pharmaceutical ingredient.
[0193] The pharmaceutical composition should also have a desired shelf life according to the International Conference on Harmonization published by the U.S. Food and Drug Administration.
[0194] Tablet formulations can be prepared by any suitable tabletting method, but direct compression is particularly advantageous and economical when possible because it involves fewer processing steps than other processes. Tablets (including particles and pellets) can also be prepared using any suitable technology, including wet granulation, dry granulation and roller compaction. In an exemplary embodiment, wet granulation or direct compression is used. Suitably, wet granulation. Before ingredients (e.g., 6-TG and polyethylene oxide polymers and / or other core ingredients) are blended into tablets, it is preferably noted that substantially uniform or homogeneous blending is ensured. For example, a sample of the blend can be taken to test uniformity, preferably, the amount of 6-TG of the sample or the relative standard deviation changes are less than about 6%, or about 5%, or about 4%, or preferably about 2%. For example, for detailed information on the standard process for obtaining blending uniformity, see "Journal of Pharmaceutical Innovation (J Pharm Innov)" (2015) 10:76-83 and "Journal of Pharmaceutical Innovation" (2015) 10:84-97.
[0195] Dosage Levels
[0196] In a specific embodiment, the optimal treatment regimen and therefore the method of the present invention includes administering a total daily dose of 6-TG of about 0.1 mg / kg, 0.2 mg / kg or 0.3 mg / kg body weight to about 2.5 mg / kg body weight (e.g., 0.1 mg / kg body weight to 2.5 mg / kg body weight). Suitably, the total daily dose of 6-TG is 0.1, 0.2 or 0.3 mg / kg body weight to 2.0 mg / kg body weight; 0.1, 0.2 or 0.3 mg / kg body weight to 1.5 mg / kg body weight; or 0.1, 0.2 or 0.3 mg / kg body weight to 1 mg / kg body weight. More suitably, the total daily dose of 6-TG is 0.1, 0.3, 0.4 or 0.5 mg / kg body weight to 1.0 mg / kg body weight, and even more suitably, the total daily dose of 6-TG is about 0.1, 0.3, 0.4 or 0.5 mg / kg body weight to about 0.8 mg / kg body weight. Suitably, the dose is administered as a once daily dose.
[0197] Those skilled in the art will appreciate that the above dosage, although stated as daily dosage, may not be daily administration. For example, 0.1mg / kg / body weight to 1mg / kg / body weight 6-TG daily dosage can be applied every 2, 3, 4, 5, 6 or 7 days (or otherwise). In an illustrative embodiment, 60 kilograms of individuals (e.g., adults) receiving a 6-TG daily dosage of 1mg / kg / body weight (i.e., a daily dosage of 60mg) can receive 60mg / days, or can instead receive 120mg every 2 days, or receive 180mg every 3 days, etc. In another illustrative embodiment, 20 kilograms of individuals (e.g., children) can receive the same 6-TG daily dosage (1mg / kg / body weight), which is equivalent to 20mg / days, or 40mg / 2 days, or 60mg / 3 days, etc. In another illustrative embodiment, a 60 kg individual (e.g., an adult) receiving a daily dose of 0.2 mg / kg / body weight of 6-TG (i.e., a daily dose of 12 mg) can receive 12 mg / day, or can instead receive 24 mg every 2 days, or 36 mg every 3 days, etc. In another illustrative embodiment, a 20 kg individual (e.g., a child) can receive the same daily dose of 6-TG (0.1 mg / kg / body weight), which is equivalent to 2 mg / day, or 4 mg / 2 days, or 6 mg / 3 days, etc.
[0198] Therefore, in certain embodiments, the composition of the present invention including 6-TG includes about 0.1 mg / kg body weight to 2.5 mg / kg body weight of 6-TG. Suitably, the composition includes about 0.1 mg / kg body weight to 2.0 mg / kg body weight of 6-TG. Suitably, the composition includes about 0.1 mg / kg body weight to 1.5 mg / kg body weight of 6-TG. Suitably, the composition includes about 0.1 mg / kg body weight to 1.0 mg / kg body weight of 6-TG. Suitably, the composition includes about 0.1 mg / kg body weight to 0.8 mg / kg body weight of 6-TG. Suitably, the composition includes about 0.1 mg / kg body weight to 0.5 mg / kg body weight of 6-TG. Suitably, the composition includes about 0.3 mg / kg body weight to 2.5 mg / kg body weight of 6-TG. Suitably, the composition comprises 0.4 mg / kg to 1 mg / kg body weight of 6-TG, more suitably, the composition comprises 0.5 mg / kg to 1.0 mg / kg body weight of 6-TG, and even more suitably, the composition comprises 0.5 mg / kg to 0.8 mg / kg body weight of 6-TG.
[0199] The exact dosage of 6-TG in the compositions of the present invention may depend on a variety of factors, such as the disease or condition to be treated, the progression or stage of the disease or condition and / or the individual to be treated, including the age, sex, height and / or weight of the individual. It is expected that practitioners in the art can determine the exact dosage. In determining the dosage, practitioners can assess the severity of the disease or condition, or the severity of the symptoms of the disease or condition, the individual's clinical history and responsiveness to previous therapies, including any history of previous recurrence of the disease or condition. The expected dosage can be easily determined without excessive experimentation.
[0200] Examples
[0201] Example 1: Preparation of 10 mg 6-TG oral formulation
[0202] Core preparations
[0203] 10 mg of polyethylene oxide (PEO 2M) with a molecular weight of about 2,000,000 g / mol was added to 10 mg of 6-TG and blended for 5 minutes. 336.39 mg of PEO 2M was then added to the mixture and blended for 5 minutes. 3.6 mg of magnesium stearate was then added to the mixture and blended for 2 minutes.
[0204] The final w / w % amounts of the components in the core are listed in Table 1. The mixture was then compressed to form the core (Formulation 1).
[0205] Coating
[0206] The cores were coated with a mixture of Evonik Eudragit L30 D-55, PlasAcryl HTP20 and water as listed in Table 1.
[0207] Evonik Eudragit L30 D-55 is a premixed aqueous dispersion of a methacrylic acid-ethyl acrylate copolymer having a molecular weight of about 320,000 g / mol.
[0208] PlasAcryl HTP20 is a premixed aqueous plasticizer that includes an anti-tack agent (glyceryl monostearate), a plasticizer (triethyl citrate), and a surfactant (polysorbate 80).
[0209] To coat the core formulation, 570 g of Evonik Eudragit L30 D-55 aqueous dispersion was dispensed into a container containing 284.5 g of purified water and stirred using an overhead mixer. 145.5 g of PlasAcryl HTP20 was added to the dispersion under continuous stirring. The mixture was stirred for 30 minutes and then sieved into another container ready for application. The tablets were placed in a coating pan and the pan was rotated at 15-45 rpm. During this period, the tablets were heated to 30-40 degrees Celsius under a stream of hot air. The coating mixture was pumped from the stirring vessel to a nozzle located approximately 10 cm above the tablets. Pressurized air was used to atomize the coating mixture, thereby producing a fine spray that coated the rotating tablets. The coating was applied until the tablets increased by approximately 10% w / w.
[0210] In another example, compressed cores are coated with a mixture of Colorcon Acryl-EZE 93F 19255, a plasticizer (triethyl citrate) and an optional defoamer (simethicone). Acryl-EZE 93F 19255 is a premixed powder for aqueous dispersion. AcrylEZE is a ready-to-use mixture containing methacrylic acid copolymer, talc, optional pigment, polyethylene glycol, silicon dioxide, sodium bicarbonate and sodium lauryl sulfate.
[0211] Table 1: Exemplary 6-TG oral formulation 1
[0212]
[0213] Example 2: In vitro dissolution testing procedure
[0214] 2.1 Equipment parameters
[0215] The UV-Vis spectrophotometer system parameters are shown in Table 2.
[0216] Table 2: UV-Vis spectrophotometer system
[0217] Cuvette 5mm Wavelength of interest for fixed wavelength measurements 341nm (±1nm), the wavelength of maximum absorbance UV-Vis light source conversion 370.0nm
[0218] The dissolution bath system parameters are shown in Table 3.
[0219] Table 3: Dissolution bath system
[0220] Device Basket (device 1) Medium volume at the end of dissolution: 900mL(900g) temperature 37±0.5℃ speed 100±4rpm Sampling volume 20mL
[0221] 2.2 General Dissolution Testing Procedure
[0222] The procedure followed is as follows:
[0223] 1. Place one tablet into each basket.
[0224] 2. Perform dissolution testing using specified equipment parameters.
[0225] 3. At the sampling time point, extract 20 mL of sample from each container through the cannula filter. When performing the dissolution profile, replace the same extraction volume with the dissolution medium to maintain the volume in each container.
[0226] 4. Immediately filter each sample through a syringe filter.
[0227] Using a 5 mm quartz cuvette, UV analysis was performed as follows:
[0228] 1. Obtain the spectra of the following solutions in the range of 291 to 391 nm (i.e., 341 ± 50 nm):
[0229] ●Blank (filtered dissolution medium) vs. blank
[0230] ● Check the standard working solution and blank
[0231] ●Dissolution samples and blanks
[0232] 2. In the photometric mode, analyze the following solutions at the wavelength of maximum absorbance of the check standard working solution (i.e., 341 ± 1 nm as determined from the spectrum):
[0233] ●Blank and blank
[0234] ●Blank space and air
[0235] ● Check the standard working solution and blank
[0236] ●Calibration standard working solution and blank
[0237] ●Dissolution sample solution and blank
[0238] ●Calibration standard working solution and blank
[0239] ●Blank and blank
[0240] The % dissolution for each sample was calculated using the calculation set forth below.
[0241] program
[0242] The system suitability acceptance criteria are:
[0243] Spectral analysis:
[0244] 1. Blank to blank spectra within ±0.005AU across the wavelength range of 291 to 391 nm.
[0245] 2. Check that the λmax of the standard working solution should be 341±1nm.
[0246] 3. Check that the λmax difference between the standard working solution and the sample solution should not exceed 2nm.
[0247] Fixed wavelength measurement:
[0248] 1. At the beginning and end of the analysis, the blank and blank readings are within 0.000AU±0.005AU.
[0249] 2. Blank and air readings do not exceed 0.4AU.
[0250] 3. The difference in response factor between the check and calibration standard working solutions does not exceed 2.0%.
[0251] 4. The % difference between the readings of the calibration standard working solution at the beginning and end of the analysis shall not exceed 2.0%.
[0252] Calculation of Dissolution %
[0253] To calculate the dissolution % for each sample, the following calculation was used:
[0254]
[0255] The percentage of dissolved thioguanine in each sample was calculated using the following formula:
[0256]
[0257] in:
[0258] AU sa = absorbance of sample solution
[0259] AU std = absorbance of the calibration standard working solution at the start of the analysis
[0260] std.m = mass of thioguanine standard in calibration standard stock solution (mg)
[0261] P = Purity of Thioguanine Standard "As is" ÷ 100
[0262] LC = label claim (i.e., 10 mg / tablet)
[0263] V = dissolution volume, e.g. 900 mL for dissolution at a single pH as described below, or
[0264] The volume (mL) of dissolution medium for each stage was performed at 3 different pH (1.1, 6.5 and 6.8) as follows:
[0265] Acid stage (pH 1.1): 688 mL
[0266] Buffer stage 1 (pH 6.5): 880 mL
[0267] Buffer stage 2 (pH 6.8): 900 mL
[0268] The volume (mL) of dissolution medium for each stage was performed at 3 different pH as follows:
[0269] Acid stage (pH 1.1): 650mL
[0270] Buffer stage 1 (pH 5.5): 806 mL
[0271] Buffer stage 2 (pH 6.8): 900 mL
[0272] Examples of typical thioguanine standard UV spectra and typical sample solution UV spectra are given in Figure 7 Shown in.
[0273] The calculations used to correct for the percentage of thioguanine dissolved in each sample are shown in Table 4 below.
[0274] Table 4: Calculation of the corrected percentage of thioguanine dissolved in each sample
[0275]
[0276] in:
[0277] a, b, c, etc. = uncorrected dissolution results according to the formula in the method
[0278] x n = aliquot sampled at time point n (mL)
[0279] v n = Volume of dissolution medium in each dissolution vessel at time point n (mL)
[0280] Preparation of check and calibration solutions
[0281] To prepare the check standard stock solution or calibration standard stock solution (both 100 μg / mL thioguanine), weigh approximately 10 mg of thioguanine reference standard and transfer to a 100 mL volumetric flask. Pipette 5.0 mL of DMSO into the flask, swirl to mix, and let stand for 20 minutes to allow significant dissolution of the active, swirling every 5 minutes. Add approximately 80 mL of dissolution medium and swirl to mix. Equilibrate to room temperature and mix thoroughly by inversion before diluting to appropriate volume with dissolution medium.
[0282] To prepare the check standard working solution or calibration standard working solution (both 10 μg / mL thioguanine), pipette 5.0 mL of the check standard stock solution into a 50 mL volumetric flask. Dilute to the appropriate volume with dissolution medium and mix thoroughly by inversion.
[0283] 2.3.1 Dissolution testing at a single pH
[0284] Dissolution testing was performed at a single pH using phosphate buffer at pH 6.8. The buffer solution was prepared as follows:
[0285] Preparation of dissolution medium (pH 6.8 phosphate buffer)
[0286] To prepare 10 L: Mix 2500 mL 0.2 M KH2PO4 solution with 1120 mL 0.2 M NaOH solution. Dilute to 9 L with purified water and mix. Determine pH and, if necessary, adjust to pH 6.8 ± 0.05 with 0.2 M NaOH solution. Make up to 10 L with purified water. Mix thoroughly. Measure and record pH of the medium. Warm to about 40 °C, filter and degas.
[0287] 2.3.2 Dissolution testing at elevated pH (e.g. pH 1.1, 6.5 and 6.8)
[0288] Dissolution testing was also performed at increasing pH using the three dissolution media.
[0289] For dissolution testing at pH 1.1, 6.5, and 6.8, buffer and calibration solutions were prepared as follows:
[0290] Dissolution medium 1 (acid stage) (0.1M HCl)
[0291] To prepare 10 L of 0.1 M HCl: dilute 85 mL of hydrochloric acid to 10 L with filtered and degassed purified water.
[0292] Dissolution medium 2 (buffer stage 1): phosphate buffer pH 6.50 ± 0.05
[0293] To prepare 1 L: Mix 688 ml of 0.1 M HCl with 192 mL of 0.2 M trisodium phosphate solution. If necessary, adjust pH to 6.50 ± 0.05.
[0294] Dissolution medium 3 (buffer stage 2): phosphate buffer pH 6.80 ± 0.05
[0295] To prepare 1 L: Mix 688 ml of 0.1 M HCl with 212 mL of 0.2 M trisodium phosphate solution. If necessary, adjust pH to 6.80 ± 0.05.
[0296] Thinner
[0297] 0.01M NaOH solution. Weigh 8.0 g of sodium hydroxide into a 1000 mL volumetric flask and add 600 mL of purified water. Cool to room temperature before making up to the appropriate volume with purified water. Dilute 50 mL of the resulting solution further to 1000 mL with purified water.
[0298] blank solution
[0299] Blank: Dissolution medium 3 (phosphate buffer pH 6.80)
[0300] Blank 1: Dissolution medium 1 (0.1M HCl)
[0301] Blank 2: Dissolution medium 2 (phosphate buffer pH 6.50)
[0302] Procedure for elevated pH dissolution testing (at pH 1.1, 6.5 and 6.8)
[0303] For the dissolution test conducted at elevated pH, there were three phases, including the acid phase, buffer phase 1, and buffer phase 2. Table 5 below lists the sampling time points and replacement media for each phase.
[0304] Table 5: Sampling time points and replacement media at each stage of the elevated pH dissolution test
[0305]
[0306] Acid stage
[0307] 1. Add 688 mL of filtered and degassed 0.1 M HCl (Dissolution Medium 1) to each dissolution vessel and equilibrate to 37 ± 0.5 °C.
[0308] 2. Place one tablet into each basket and start basket rotation.
[0309] 3. After 2 hours in 0.1 M HCl, proceed immediately to buffer stage 1.
[0310] Buffering stage 1
[0311] 1. With the basket operating at the rate specified in the work plan, add 192 mL of 0.2 M trisodium phosphate equilibrated to 37 ± 0.5 °C to the fluid in the vessel (addition of the buffer should be completed within 5 minutes).
[0312] 2. Continue the operation for another hour and then proceed to buffer stage 2.
[0313] Buffering stage 2
[0314] 1. In the case of basket operation, add another 20 mL of 0.2 M trisodium phosphate equilibrated to 37 ± 0.5 °C to the fluid in the container (complete the addition of buffer within 5 minutes).
[0315] 2. Continue the process until dissolution is complete.
[0316] At each designated sampling time point, withdraw 20 mL of sample from each vessel through a 35 μm polyethylene pipette filter into a test tube and replace the withdrawn sample volume with an equal volume of the appropriate dissolution medium.
[0317] 2.3.3 Dissolution testing at elevated pH (e.g. pH 1.1, 5.5 and 6.8)
[0318] For dissolution testing at pH 1.1, 5.5, and 6.8, buffer and calibration solutions were prepared as follows:
[0319] Dissolution medium 1 (acid stage) (0.1M HCl)
[0320] The volume required for 0.1M HCl (SS585-08) is approximately 4020 mL, i.e. 650 mL x 6 = 3900 mL for the first stage, and an additional 120 mL for replacement. Solutions should be prepared using filtered and degassed purified water.
[0321] Dissolution medium 2 (buffer stage 1 replacement) (phosphate buffer pH 5.50)
[0322] To prepare 300 mL: Mix 242 mL 0.1 HCl with 58 mL 0.2 M sodium phosphate tribasic solution. Adjust pH to 5.50 ± 0.05 with 0.1 M HCl or 0.2 M sodium phosphate tribasic. Degas by sonication.
[0323] Dissolution medium 3 (buffer stage 2 replacement) (phosphate buffer pH 6.80)
[0324] To prepare 1700 mL: Mix 1300 mL 0.1 M HCl with 400 mL 0.2 M sodium phosphate tribasic solution. Adjust pH to 6.80 ± 0.05 with 0.1 M HCl or 0.2 M sodium phosphate tribasic solution. Degas by sonication.
[0325] Solution A (for buffer stage 2)
[0326] To prepare 940 mL: Combine 440 mL of 0.2 M sodium phosphate tribasic solution with 500 mL of purified water. Degas by sonication.
[0327] blank solution
[0328] Dissolution medium 3 (phosphate buffer pH 6.80).
[0329] If necessary, other pH dissolution media can be used to test different pHs.
[0330] Procedure for elevated pH dissolution testing (at pH 1.1, 5.5 and 6.8)
[0331] For the dissolution test conducted at elevated pH, there were three phases, including the acid phase, buffer phase 1, and buffer phase 2. Table 6 below lists the sampling time points and replacement media for each phase.
[0332] Table 6: Sampling time points and replacement media at each stage of the elevated pH dissolution test
[0333]
[0334] Acid stage
[0335] 1. Add 650 mL of filtered and degassed Dissolution Medium 1 to each dissolution vessel and equilibrate to 37 ± 0.5 °C in the dissolution bath.
[0336] 2. Place one tablet into each basket and start basket rotation.
[0337] 3. At the designated sampling time point (i.e., 1 or 2 hours), extract 20 mL of sample from each container through a cannula filter. Immediately after sampling, replace the same extraction volume with Dissolution Medium 1 to maintain the volume in each container.
[0338] 4. Immediately after sampling, filter an aliquot of each sample into an appropriate test tube, through an approved syringe filter, and apply the specified discard volume.
[0339] 5. Proceed immediately to buffering stage 1.
[0340] Buffer stage 1 (pH 5.5)
[0341] 1. Without stopping the instrument, add 156 mL of 0.2 M trisodium phosphate solution, which has been degassed and equilibrated to 37 ± 0.5 °C, to the volume in each container.
[0342] Note: The addition of buffer should be completed within 5 min.
[0343] 2. At the designated sampling time point (i.e., 3 hours), extract 20 mL of sample from each container through a cannula filter. Immediately after sampling, replace the same extraction volume with dissolution medium 2 to maintain the volume in each container.
[0344] 3. Immediately after sampling, filter an aliquot of each sample into an appropriate test tube, through an approved syringe filter, and apply the specified discard volume.
[0345] 4. Proceed immediately to buffering stage 2.
[0346] Buffer stage 2 (pH 6.8)
[0347] 1. Without stopping the instrument, add 94 mL of Solution A, which has been degassed and equilibrated to 37 ± 0.5 °C, to the volume in each container.
[0348] Note: The addition of Solution A should be completed within 5 min.
[0349] 2. At designated sampling time points (i.e., 4, 6, 8, 10, 12, 14, 17, 20, 23, 26, 28, and 30 hours), extract 20 mL of sample from each container through a cannula filter. Immediately after sampling, replace the same extraction volume with dissolution medium 3 to maintain the volume in each container.
[0350] 3. Immediately after sampling, filter an aliquot of each sample into an appropriate test tube, through an approved syringe filter, and apply the specified discard volume.
[0351] Example 3: Preparation and testing of 10 mg 6-TG core formulation
[0352] Various core formulations were prepared as shown in Table 7. When formed into tablets with weights as shown in the table, the dosage was 10 mg 6-TG per tablet.
[0353] Table 7: Exemplary 6-TG Core Formulations
[0354]
[0355]
[0356] Example 4: In vitro dissolution test of formulation 1
[0357] The release rate of core formulation 1 (3 tablets, each containing 10 mg 6-TG) was tested over a period of 30 hours at pH 6.8. Table 8 provides the cumulative release percentage of 6-TG in core formulation 1 over 30 hours and Figure 2 This is summarized in graphical form.
[0358] The release profile is approximately zero order (ie, linear) from about 1 to 23 hours, with a release rate of about 3-4% per hour. Nearly 100% dissolution is achieved at about 30-32 hours.
[0359] Table 8: In vitro dissolution profile of core formulation 1 at pH 6.8 over 30 hours
[0360]
[0361] *Release rate relative to previous measurements
[0362] Example 5: In vitro dissolution test of formulation 2
[0363] The release rate of core formulation 2 (3 tablets, each containing 10 mg 6-TG) was tested over a period of 30 hours at pH 6.8. Table 9 provides the cumulative release percentage of 6-TG in core formulation 2 over 30 hours and Figure 3 This is summarized in graphical form.
[0364] Over a period of about 30 hours, the release profile is approximately zero order (ie, linear), with R 2 The value is 0.987. However, during the first 1-17 hours, R 2 The value was 0.991, which indicates that the release profile was more linear during the initial 1-17 hours.
[0365] The release rate between measurements was about 2% per hour. Only about 60% dissolution was achieved at about 30 hours. Due to the lower percentage release (e.g., very long extended release), there may be concern that the active in vivo may be excreted into municipal wastewater.
[0366] Table 9: In vitro dissolution profile of core formulation 2 at pH 6.8 over 30 hours
[0367]
[0368] *Release rate relative to previous measurements
[0369] Example 6: In vitro dissolution test of formulation 3
[0370] The release rate of core formulation 3 (3 tablets, each containing 10 mg 6-TG) was tested over a 30-hour period at pH 6.8. Table 10 provides the cumulative release percentage of 6-TG for core formulation 3 over 30 hours and Figure 4 This is summarized in graphical form.
[0371] The release profile is approximately zero order (ie, linear) over a period of about 1 to 12-14 hours, with R 2 The value was 0.992 within 1-14 hours, and R 2 The value is 0.998 within 1-12 hours. 2 The value is nonlinear in 1-30 hours, where R 2 The value is 0.787 because most of the release occurs within 1-14 hours.
[0372] The release rate was about 6-8% per hour over 1-12 hours. About 92% dissolution was achieved at about 14 hours.
[0373] Table 10: In vitro dissolution profile of core formulation 3 at pH 6.8 over 30 hours
[0374]
[0375]
[0376] *Release rate relative to previous measurements
[0377] Example 7: In vitro dissolution test of formulation 4
[0378] The release rate of core formulation 4 (3 tablets, each containing 10 mg 6-TG) was tested over a period of 30 hours at pH 6.8. Table 11 provides the cumulative release percentage of 6-TG in core formulation 4 over 30 hours and Figure 5 This is summarized in graphical form.
[0379] The release curve is less linear than the above example, where R 2 The value was 0.952 within 1-36 hours, and R 2 The value was 0.971 in 1-29 hours.
[0380] About 95% dissolution was achieved at about 36 hours.
[0381] The release rate was about 3-4% per hour.
[0382] Table 11: Comparative in vitro dissolution profiles of core formulation 4 at pH 6.8 over 36 hours
[0383]
[0384]
[0385] *Release rate relative to previous measurements
[0386] Example 8: Preparation and testing of 10 mg 6-TG oral formulation
[0387] Additional illustrative examples of 6-TG oral formulations were prepared. The formulations are given in Table 12.
[0388] The tablets were prepared using the following method:
[0389] 1. Thioguanine (21.98 g) and poly(ethylene oxide) WSR N60K (40.52 g) were mixed in a container for 5 minutes.
[0390] 2. Further poly(ethylene oxide) WSR N60K (680 g) was weighed, sieved and transferred to the container and mixed for 10 minutes.
[0391] 3. Weigh magnesium stearate (7.50 g), sieve and transfer to container and mix for 2 minutes.
[0392] 4. Compress tablets weighing approximately 360 mg using a RIVA tablet press using RISE tools.
[0393] 5. The potency can be adjusted for use of Thioguanine hemihydrate or anhydrate. The potency is 10 mg per tablet.
[0394] To coat the tablets, the following process is performed:
[0395] 1. Tarred a container and dispense purified water and triethyl citrate into it.
[0396] 2. Add Acryl-EZE powder to the container and apply overhead mixing for at least 30 minutes until the suspension appears homogeneous.
[0397] 3. Before coating, pass the suspension through a mesh screen.
[0398] 4. Load the tablets into a fluid bed dryer preheated to 60°C.
[0399] 5. Perform a test spray without tablets to ensure the suspension nozzle is compatible and adjust the spray if necessary.
[0400] 6. Start coating at a slow rate and increase throughout the run. The tablet bed temperature must not exceed 65°C.
[0401] 7. Weigh the total mass of the tablets after drying for 30 minutes after coating. Coat the tablets to a target weight gain of 10%, e.g., total tablet weight x 1.10.
[0402] Table 12: Exemplary 6-TG Oral Formulations
[0403]
[0404] Example 9: In vitro dissolution testing of 6-TG oral formulation (Formulation 5 with enteric coating)
[0405] Formulation 5 was subjected to dissolution testing according to the in vitro dissolution testing procedure in Example 2, with pH 1.1 at 1-2 hours, pH 6.5 at 3 hours, and pH 6.8 at 4-36 hours.
[0406] Table 13 provides the cumulative release percentage of 6-TG in the formulations within 36 hours and Figure 6 This is summarized in graphical form.
[0407] The release curve is approximately zero order (ie, approximately linear) over a period of about 4 to 26 hours (at pH 6.8), with R 2 It is 0.994.
[0408] At pH 1.1, only about 1% solubility was observed after 2 hours.
[0409] During the first 3-26 hours, the release rate was about 3-4.5% per hour.
[0410] About 98% dissolution was achieved at about 32 hours.
[0411] Table 13: In vitro dissolution profile of Formulation 5 over 36 hours (pH 1.1 at 1-2 hours, pH 6.5 at 3 hours, pH 6.8 at 4-36 hours)
[0412]
[0413]
[0414] *Release rate relative to previous measurements
[0415] Example 10: Preparation of 10 mg 6-TG oral formulation
[0416] Additional illustrative examples of 10 mg 6-TG oral formulations were prepared according to the same general method as Example 8. The formulations are given in Table 14.
[0417] Table 14: Exemplary 6-TG Oral Formulations
[0418]
[0419] Example 11: In vitro dissolution test of the 6-TG oral formulation of Example 10
[0420] The formulation of Example 10 was subjected to dissolution testing according to the in vitro dissolution testing procedure in Example 2, with pH 1.1 at 1-2 hours, pH 5.5 at 3 hours, and pH 6.8 at 4-30 hours.
[0421] Table 15 provides the cumulative release percentage of 6-TG in the formulations within 30 hours and Figure 8 This is summarized in graphical form.
[0422] The release curve is approximately zero order (ie, approximately linear) over a period of about 4 to 23 hours (at pH 6.8), with R 2 is 0.995, and within about 4 to 26 hours (at pH 6.8), R 2 It is 0.994.
[0423] The dissolution was 0% after 2 hours at pH 1.1 and also 0% after 1 hour at pH 5.5.
[0424] During the first 3-26 hours, the release rate was about 3-4.5% per hour.
[0425] A dissolution of about 93% was achieved in about 30 hours (26 hours at pH 6.8).
[0426] Table 15: In vitro dissolution profile of the formulation of Example 10 over 30 hours (at pH 1.1 at 1-2 hours, at pH 5.5 at 3 hours, at pH 6.8 at 4-30 hours)
[0427]
[0428] *Release rate relative to previous measurements
[0429] Example 12: Administration of 10 mg 6-TG oral formulation to a patient
[0430] Male subjects (Caucasian), aged 60-70 years, weighing 90-110 kg, with a 15-year history of ulcerative colitis (UC), took one enteric-coated 10 mg 6-TG extended-release oral tablet (formulation of Example 10) and mesalamine (2 g) daily for 3 months, and then took only the 10 mg 6-TG extended-release tablet for 7 months.
[0431] The subject had previously been treated with mercaptopurine (50 mg to 75 mg alternating doses daily) and mesalamine (2 g daily). In the past, the subject took adalimumab (anti-TNF antibody) and previously required a course of steroid therapy to achieve remission.
[0432] One to two months before taking 6-TG extended-release oral tablets (concomitant treatment with mercaptopurine / mesalamine), subjects underwent the following endoscopic and microscopic evaluations:
[0433] ● Endoscopic evaluation: Active disease consistent with ulcerative colitis was found from the rectum to the sigmoid colon. The Ulcerative Colitis Endoscopic Severity Index (UCEIS) was V1E1B0 equal to 2 / 8, and the Mayo score was 1. The rest of the ascending colon, the colon anastomosis, and the transverse colon appeared normal.
[0434] Microscopic examination: Evaluation revealed colonic mucosa with glandular shortening and branching associated with diffuse inflammation including chronic inflammatory cells and moderate numbers of neutrophils. Regenerative epithelial changes were present. No pathogens, granulomas, dysplasia, or malignancy were found. In conclusion, biopsy of the distal sigmoid colon showed chronic active colitis.
[0435] Approximately 10 months after initiation of daily administration of extended-release 6-TG tablets (and 7 months after initiation of monotherapy with 6-TG), subjects underwent the following endoscopic and microscopic evaluations:
[0436] ● Endoscopic summary: UCEIS V0 E0 B0 = 0 / 8 for the entire colon and rectum, Mayo score 0. Only one small plaque with a small aphthous ulcer was present in the distal sigmoid colon (Mayo 1, UCEIS V1 B0 E1 = 2 / 8).
[0437] ● Microscopic summary: Sections of the rectal mucosa showed mild crypt distortion and Paneth cell metaplasia. There was no evidence of cryptitis, ulceration, granulomas, viral inclusions, dysplasia, or malignancy. In conclusion, the biopsy showed mild chronic proctitis.
[0438] Treatment with extended-release 6-TG oral tablets showed improvement compared to previous endoscopic and microscopic summaries. The subjects showed improvement even after seven months of monotherapy with extended-release 6-TG tablets, despite previous treatment with mercaptopurine and mesalamine.
[0439] Comparison of Thiopurine Metabolites in Red Blood Cells (RBCs)
[0440] While taking the 6-TG extended release tablets, the subjects' metabolite levels were monitored by blood tests. 6-TGN and 6-MMP levels were consistently low. Table 16 shows an example of blood test results obtained at two different time points.
[0441] Table 16: Results of blood tests monitoring thiopurine metabolite levels in subjects
[0442]
[0443] For comparison, patients treated with azathioprine or 6-mercaptopurine for inflammatory bowel disease were monitored with blood tests, with dose adjustments aimed at achieving 6-TGN concentrations of 235 to 450 pmol / 8 x 10(8) RBC. This range was designed to optimize efficacy while minimizing the risk of toxicity. Concentrations below 235 pmol / 8 x 10(8) RBC were associated with a higher risk of treatment failure, while concentrations above 450 pmol / 8 x 10(8) RBC were associated with an increased risk of leukopenia, although this sometimes occurred at lower concentrations.
[0444] Receiving immediate-release 6-thioguanine therapy for IBD (eg, Thiosix TM Tablets or Lanvis TM Patients taking 1 / 2 tablet of the drug (average daily dose for these patients was 20 mg) typically had 6-TGN levels of 800 to 1200 pmol / 8 x 10(8) RBCs during the treatment interval.
[0445] 6-MMP is generally considered a toxic metabolite. RBC levels are not associated with treatment efficacy. 6MMP>5700pmol / 8x10(8)RBC is associated with increased risk of hepatotoxicity. Low 6-TGN and significantly higher 6-MMP (i.e., ratio of 6MMP to 6TGN>20) are associated with increased risk of poor response to standard therapy.
[0446] Table 17 shows examples of 6-TGN and 6-MMP concentrations in RBCs at different time points in subjects treated with mercaptopurine (prior treatment).
[0447] Table 17: Blood test results of subjects treated with mercaptopurine (for comparison)
[0448]
[0449] As shown in Table 16, compared with standard 6-TG therapy (e.g. Thiosix TM Tablets or Lanvis TMSystemic levels of 6-TGN and 6-MMP were lower with extended-release 6-TG treatment compared to normal treatment interval levels for 1 / 2 tablet (0.5 mg / kg) and / or compared to normal treatment interval levels expected with azathioprine or 6-mercaptopurine treatment and / or compared to the subject's prior levels while on mercaptopurine treatment. This may be beneficial from a toxicity / safety perspective.
[0450] For comparison, a 2022 paper published in Inflammatory Bowel Diseases (“Rectally Administrated Thioguanine for Distal Ulcerative Colitis: A Multicenter Case Series”, Crouwel et al. Inflammatory Bowel Diseases, 2022, XX, 1–5, https: / / doi.org / 10.1093 / ibd / izac195 , published in advance access on September 13, 2022), noted that after a median of 33 days, the median 6-TGN levels in three patients treated with thioguanine (20 mg) enema alone were 140, 153, and 315 pmol×10^8 RBC, respectively. After a median of 15 days (IQR, 10-20), the median 6-TGN levels in seven patients treated with thioguanine (20 mg) suppositories alone were 32 pmol×10^8 RBC (IQR, 15-93). Therefore, the 6-TGN concentration in RBCs of the 10 mg 6-TG extended-release oral tablet is closer to these topically applied treatments (i.e., suppositories and enemas) than the previously known orally administered immediate-release tablets.
Claims
1. A pharmaceutical composition comprising 6-thioguanine (6-TG) and a polyethylene oxide polymer having a molecular weight between about 900,000 g / mol and about 9,000,000 g / mol.
2. The pharmaceutical composition according to claim 1, wherein the composition is formulated for oral administration.
3. The pharmaceutical composition of claim 1 or 2, wherein the molecular weight of the polyethylene oxide polymer is greater than about 900,000 g / mol and less than about 7,000,000 g / mol.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the molecular weight of the polyethylene oxide polymer is about 2,000,000 g / mol.
5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the polyethylene oxide polymer comprises essentially a single approximate molecular weight.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the ratio of the 6-TG to the polyethylene oxide polymer is about 1:20 to 1:
50.
7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the composition is a tablet comprising a core and an enteric coating.
8. The pharmaceutical composition according to claim 7, wherein the tablet comprises about 1 to 50 mg of 6-TG.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the polyethylene oxide polymer comprises about 60 to 98% w / w of the pharmaceutical composition.
10. The pharmaceutical composition according to any one of claims 7 to 9, wherein the polyethylene oxide polymer comprises about 70 to 99% w / w of the core of the tablet.
11. The pharmaceutical composition according to any one of claims 7 to 10, wherein the enteric coating comprises cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, methacrylic acid copolymer or a combination thereof.
12. The pharmaceutical composition according to claim 11, wherein the enteric coating further comprises one or more excipients selected from the group consisting of plasticizers, anti-adherents, surfactants, defoaming agents and mixtures thereof.
13. The pharmaceutical composition according to any one of claims 7 to 12, wherein the enteric coating is capable of dissolving at a pH of at least 5.
5.
14. The pharmaceutical composition according to any one of claims 1 to 13, wherein the pharmaceutical composition is formulated to provide approximately zero-order kinetics of 6-TG release.
15. The pharmaceutical composition of any one of claims 1 to 14, wherein the pharmaceutical composition provides at least about 30% release of the 6-TG in about 10 hours at about pH 5.5 to about pH 7.5 in vitro.
16. The pharmaceutical composition of any one of claims 1 to 15, wherein the pharmaceutical composition provides at least 70% release of the 6-TG in about 20 hours at about pH 5.5 to about pH 7.5 in vitro.
17. The pharmaceutical composition of any one of claims 1 to 16, wherein the pharmaceutical composition provides at least 85% release of the 6-TG in about 30 hours at about pH 5.5 to about pH 7.5 in vitro.
18. The pharmaceutical composition of any one of claims 1 to 17, wherein the pharmaceutical composition provides less than about 10% release of the 6-TG in about 2 hours at less than about pH 5.5 in vitro.
19. The pharmaceutical composition of any one of claims 1 to 18, wherein the pharmaceutical composition provides less than 80% release of the 6-TG in about 10 hours at about pH 5.5 to about pH 7.5 in vitro.
20. The pharmaceutical composition according to any one of claims 1 to 19, wherein the pharmaceutical composition: provides at least 85% release of said 6-TG in about 30 hours at about pH 5.5 to about pH 7.5 in vitro, and In vitro at about pH 5.5 to about pH 7.5 provides less than 80% release of the 6-TG in about 10 hours.
21. A method for treating a disease or condition responsive to 6-TG in the distal intestine of a subject in need thereof, the method comprising administering a pharmaceutical composition according to any one of claims 1 to 20, wherein the 6-TG is released in the distal intestine.
22. Use of a polyethylene oxide polymer having a molecular weight of between about 900,000 and about 9,000,000, optionally comprising an enteric coating, in the manufacture of a medicament, wherein the medicament is formulated to treat a disease or condition of the distal intestine that is responsive to 6-TG by releasing the 6-TG in the distal intestine.
